Metastases are responsible for the majority of cancer-related deaths. Although genomic heterogeneity within primary tumors is associated with relapse, heterogeneity among treatment-naïve metastases has not been comprehensively assessed. We analyzed sequencing data for 76 untreated metastases from 20 patients and inferred cancer phylogenies for breast, colorectal, endometrial, gastric, lung, melanoma, pancreatic, and prostate cancers. We found that within individual patients, a large majority of driver gene mutations are common to all metastases. Further analysis revealed that the driver gene mutations that were not shared by all metastases are unlikely to have functional consequences. A mathematical model of tumor evolution and metastasis formation provides an explanation for the observed driver gene homogeneity. Thus, single biopsies capture most of the functionally important mutations in metastases and therefore provide essential information for therapeutic decision-making.
T he clonal evolution model of cancer proposes that cells accrue advantageous mutations and clonally expand so that these mutations are eventually present in all tumor cells (1) (2) (3) (4) . Recent studies reported mutations in putative driver genes that were only present in subpopulations of tumor cells (5, 6) . The extent to which the acquisition of advantageous mutations continues after the initiation of the primary tumor (7) or during metastasis formation is unknown (8, 9) . The growing list of putative driver genes and the increased sensitivity of next-generation sequencing have facilitated the discovery of subclonal driver gene mutations within a tumor (5, 10) . Nevertheless, the evolutionary dynamics and the clinical importance of driver gene mutation heterogeneity in solid tumors are not fully understood.
Cells acquire a few mutations during each division because of imperfect DNA replication; hence, any population of cells is genetically heterogeneous (11) . Because cancer cells continue to divide after cancer initiation, many new mutations are expected to be present in tumor subpopulations. However, to assess functional heterogeneity, advantageous mutations in putative driver genes must be distinguished from neutral replication errors in those genes. For example, within oncogenes, only few recurrently mutated positions are functional, and therefore, many mutations-even in driver genes-may not have important functional consequences. Moreover, although metastatic disease is responsible for most cancer-related deaths, the heterogeneity of driver gene mutations has predominantly been evaluated in primary tumors. Biopsies of metastatic lesions are not readily available and typically are acquired after exposure to toxic and mutagenic chemotherapies. These treatments can induce selective bottlenecks and confound the interpretation of genetic alterations.
Because driver gene mutations increasingly inform clinical treatment decisions, undetected driver heterogeneity among metastases poses a barrier to the success of this precision medicine approach (12) . If the founding cells of different metastases carry distinct driver gene mutations, disease progression and treatment could be fundamentally more complex than expected from a primary tumor biopsy alone. Additional driver gene mutations might be present in all or in a subset of metastases (Fig. 1) . In both scenarios, more biopsies would be necessary for accurate diagnosis and optimal treatment. Here, we comprehensively analyzed the evidence for driver gene mutation heterogeneity among untreated metastases across cancer types. We also developed a mathematical model to determine the evolutionary mechanisms that give rise to intermetastatic driver mutation heterogeneity.
We analyzed data from 20 cancer patients for whom genome-or exome-wide sequencing was performed for at least two distinct treatmentnaïve metastases (13) (14) (15) (16) (17) (18) (19) . In total, we studied 115 samples, including 76 untreated metastases samples from diverse tissues (mean of 3.8 and median of 3 metastases per patient) ( fig. S1 and table S1). We assessed somatic mutations of patients with pancreatic, endometrial, colorectal, breast, gastric, lung, melanoma, and prostate cancer ( Fig. 2A) . We classified nonsynonymous variants into putative driver and passengers mutations according to the The Cancer Genome Atlas consensus list of 299 putative driver genes (10) . To allow for a consistent interpretation of driver gene mutation heterogeneity, we excluded two hypermutated subjects with more than 1000 nonsynonymous mutations and focused on the remaining 18 subjects. In these subjects, we found a median of 4.5 mutated driver genes (range 2 to 18) ( Fig. 2A) .
To determine the evolutionary timing of somatic mutations, we inferred cancer phylogenies and mapped all variants onto evolutionary trees (supplementary materials, materials and methods, and fig. S2 ) (20) . We classified mutations into those present in all metastases (MetTrunk; hereafter referred to as "trunk") and those present in a subset of metastases (MetBranch; hereafter referred to as "branch") (Fig. 2B) . We observed similar numbers of nonsynonymous or splice-site variants (hereafter referred to as nonsynonymous) in both categories ( Fig. 2A) . By contrast, trunks exhibited a twofold enrichment of the ratio of driver gene mutations to nonsynonymous mutations compared with branches (9.1 versus 4.0%; two-sided paired t test, P = 0.004) (Fig. 3A) . Nevertheless, we observed mutations in driver genes that were heterogeneous among metastases for 12 of 18 subjects.
To investigate whether heterogeneous mutations in putative driver genes were likely to be functional, we used a variety of approaches. We found that a large proportion of nonsynonymous variants in driver genes along trunks were previously detected at least once in other cancers [Catalogue Of Somatic Mutations In Cancer (COSMIC); 37.8%, 31 of 82], whereas a much smaller proportion along branches was present in COSMIC (15.6%, 5 of 32; two-sided Fisher's exact test, P = 0.025) (Fig. 3B ). The fraction of driver gene mutations in branches in COSMIC was in fact similar to that of passenger gene mutations in either trunks or branches (14.1%, 128 of 905, and 12.5%, 89 of 712). Because mutations that are true drivers are often recurrent, we investigated how frequently identical nonsynonymous variants were found in COSMIC. Whereas variants in driver genes along trunks on average occurred in 0.32% COSMIC samples (occurrence mean of 82.0 in 25,516 COSMIC samples), driver gene mutations acquired along branches occurred more than 100-fold less frequently (0.0016%; Wilcoxon rank-sum test, P = 0.008) (Fig. 3C) .
We then used several methods to predict the functional impact of 1755 nonsynonymous variants along trunks and branches. We found that driver gene mutations acquired along trunks were more likely to have predicted functional consequences (Fig. 3, D to F, and fig. S3 ). Variants with the most likely protein-changing effects (mutation consequences with high impact, such as frameshift or nonsense mutations) were frequently observed in driver genes along trunks but rarely observed along branches (30.5 versus 6.3%; two-sided Fisher's exact test, P = 0.006) (Fig. 3D) . The frequency of high-impact variants in driver genes along branches was no higher than that in passenger genes. FATHMM (21) predicted significantly stronger functional effects for driver gene mutations along trunks than along branches (mean scores of -2.1 versus 1.0; scores below -0.75 indicate likely driver mutation; twosided Wilcoxon rank-sum test, P < 0.001) (Fig.  3E) . Similarly, CHASMplus (22) predicted significantly higher gene-weighted scores for driver gene mutations along trunks than along branches (mean scores 0.47 versus 0.16; higher values indicate likely functional effects; two-sided Wilcoxon rank-sum test, P < 0.001) (Fig. 3F) .
To identify the evolutionary determinants of intermetastatic heterogeneity, we developed a mathematical framework in order to assess how rates of growth, mutation, and dissemination give rise to driver gene mutation heterogeneity (supplementary text) (23, 24) . The original clone in the primary tumor grows with a rate of r 0 = b 0 -d 0 per day (birth rate is b i and death rate is d i for each clone i) and disseminates cells to distant sites with rate q 0 per day (Fig. 4A) . When a cell divides, a daughter cell can acquire an additional driver mutation with probability u. This model produces intermetastatic heterogeneity if not all detectable metastases were seeded from the same subclone in the primary tumor.
Following previously measured growth and selection parameters, we assume a growth rate of r 0 = 1.24% per day and a relative growth advantage of a driver gene mutation of s = 0.4% (s = b i /b 0 -1) (25, 26) . To mimic the composition of our cohort, we considered the first four metastases that reach a detectable size of 10 8 cells (~1 cm 3 ). We found that the probability of intermetastatic driver heterogeneity is 10.5% (d = 0.2475, q = 10
) (Fig. 4) . The original founding clone of the primary tumor most likely seeds all detectable metastases (Fig. 1A, green cells) . The increased growth rate conferred by a new driver mutation is insufficient to compensate for the time spent waiting for the driver mutation to occur (figs. S4 and S5).
The model reveals that the probability of observing intermetastatic driver heterogeneity increases when the primary tumor grows very slowly before metastases are seeded, the average growth advantage of additional driver mutations is very large, and the driver gene mutation rate is high (fig. S6C) . By contrast, a high dissemination rate produces less intermetastatic heterogeneity because metastases are established before driver subclones greatly expand (Fig. 4E and fig. S7C ). For very high driver growth advantages but slowly growing cancers, another scenario is possible: that all metastases are seeded from the same highly advantageous subclone (Fig. 1B) . Last, if driver mutations instead increase the dissemination rate, an almost 10-fold increase is required to produce intermetastatic driver heterogeneity ( Fig. 4F and fig. S8 ).
In real patients, we expect less intermetastatic heterogeneity for several reasons. First, driver gene mutations may not confer the same advantage in the microenvironment of the primary tumor and of a distant site, reducing the probability of heterogeneity ( fig. S9) . Second, primary tumor growth may slow down because of space or nutrient constraints or surgical removal, also reducing the expected intermetastatic heterogeneity ( fig. S10 ). Third, advanced cancer cells have already acquired multiple driver gene mutations in various pathways, possibly reducing the number of additionally available driver gene mutations that confer a substantial selective advantage ( fig. S6B) .
Overall, we observed a depletion of heterogeneous mutations in putative driver genes among metastases (Fig. 3) . Moreover, the majority of those that were observed had only weak or no predicted functional effects. These results are compatible with multiple recent studies on neutrally evolving cancers after transformation (7, 27, 28) . However, the mathematical framework demonstrates that a lack of intermetastatic driver heterogeneity does not imply neutral evolution but can also be explained by various other factors, Reiter PT regions and metastases exhibit driver mutation heterogeneity.
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B C *** * *** *** ** *** *** *** *** ** * *** *** *** *** *** including primary tumor growth dynamics (Fig. 4) . Furthermore, growth rates may saturate and fitness gains of additional driver gene mutations become smaller because available resources (such as nutrients and oxygen) are already almost optimally utilized-a phenomenon that is observed in bacterial evolution (29) .
Several limitations of this study should be noted. First, we exclusively focused on singlenucleotide variants and small insertions and deletions because their functionality can be predicted with multiple methods, and their heterogeneity has immediate clinical consequences for therapy selection (12) . We did not assess recurrent noncoding, copy-number, or epigenetic alterations because functional prediction methods for them are not yet available. Second, we cannot exclude the possibility that mutations in yetundiscovered driver genes of metastases are heterogeneous. Third, we could not evaluate micrometastases that are not visible clinically.
Because therapy selection and treatment success of previously untreated patients increasingly depends on the identification of genetic alterations, it will be critical to extend this analysis to larger cohorts and more cancer types in order to investigate whether minimal driver gene mutation heterogeneity is a general phenomenon of advanced disease. This pan-cancer analysis of untreated metastases suggests that a single biopsy accurately represents the driver gene mutations of a patient's metastases. 
